Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study

https://doi.org/10.1016/0277-5379(86)90142-2Get rights and content

Abstract

Adjuvant chemotherapy comprising Adriamycin (ADM) and Methotrexate (MTX) with Citrovorum Factor (CF) was administered on a randomization basis to 2 groups of patients with osteosarcoma after surgical ablation of the primary tumor. One group received high dose MTX (regimen I) and the other moderate dose MTX (regimen II). In both groups a short period of heparin treatment was also administered to prevent neoplastic emboli during surgery. All patients were free of metastasis at the beginning of therapy. The efficacy of therapy was determined by recording the percentage of continuously disease-free patients. This was compared to the disease-free survival in 132 patients previously treated with other ADM or ADM-MTX regimens and to a group of 39 patients treated during this period with amputation only. The latter did not receive adjuvant chemotherapy for a variety of reasons and are equated to a concurrent control group. Over the ensuing 27–66 months, 31 of 56 patients (55%) treated with regimen I and 25 of 50 (50%) treated with regimen II were disease-free. The overall disease-free survival in both regimens was 53%. This is similar to the 132 patients treated with previous adjuvant chemotherapy protocols (45–50%). However, the percentage of continuously disease-free patients treated with adjuvant chemotherapy was significantly better than the 39 patients (12%) treated contemporaneously with surgery only (P < 0.0005). Survival in the latter is similar to that of historical control patients. These results do not suggest any change in the natural history of osteosarcoma and reveal benefits which may accrue with adjuvant chemotherapy. These results also demonstrate that in adjuvant treatment of osteosarcoma performed with ADM and MTX the high and the moderate doses of MTX are equally efficacious.

References (29)

  • N Jaffe et al.

    Adjuvant methotrexate and citrovorum factor treatment of osteosarcoma

    New Engl J Med

    (1974)
  • N Jaffe et al.

    High-dose methotrexate in osteogenic sarcoma

  • L.J. Ettinger et al.

    Adjuvant chemotherapy and cis-diamminechlorplatinum (cysplatinum) in primary osteosarcoma

    Cancer

    (1981)
  • C Pratt et al.

    Adjuvant multiple drug chemotherapy for osteosarcoma of the extremities

    Cancer

    (1977)
  • G Rosen et al.

    Primary osteogenic sarcoma: eight years experience with adjuvant chemotherapy

    J Cancer Res Clin Oncol

    (1983)
  • W.W. Sutow et al.

    Adjuvant chemotherapy in primary treatment of osteogenic sarcoma

    Cancer

    (1975)
  • E.P. Cortes et al.

    Adriamycin (ADM) alone versus ADM and high dose methotrexate citrovorum factor rescue (HDMTX-CF) as adjuvant to operable primary osteosarcoma: a randomized study by cancer and leukemia gray B

  • R Jenkin et al.

    Osteosarcoma: a preliminary report of a trial of adjuvant chemotherapy

  • W.A. Bleyer et al.

    Improved three-year disease-free survival in osteogenic sarcoma

  • G Rosen

    Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience

    Orthopedics

    (1985)
  • H.C. Hoover et al.

    Osteosarcoma

  • Guerra A, Bacci G, Bertoni F et al. Resection and temporary stabilization with Kuntscher rod (or plate or external...
  • M. Campanacci et al.

    The treatment of osteosarcoma of the extremities: twenty years experience at the Istituto Ortopedico Rizzoli

    Cancer

    (1984)
  • N Mantel et al.

    Statistical aspects of the analysis of data from retrospective studies of disease

    J Nat Cancer Inst

    (1959)
  • Cited by (62)

    • Does intensified chemotherapy increase survival outcomes of osteosarcoma patients? A meta-analysis

      2018, Journal of Bone Oncology
      Citation Excerpt :

      The obtained 12 studies were all comparative studies between intensified and conventional chemotherapy strategies. The characteristics of the 12 included studies were listed in Table 1 [15–26], of which 8 studies were RCT and 4 studies were CCT. A total of 4112 patients were involved in this meta-analysis.

    • Sarcomas of bone

      2018, DeVita, Hellman, and Rosenberg's Cancer: Principles &amp; Practice of Oncology
    View all citing articles on Scopus

    Supported in part by a grant of the National Council for Research, project “Oncology” n. 84.00623.44.

    View full text